Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Tecentriq (atezolizumab) is the first drug approved approved for advanced alveolar soft part sarcoma, a rare cancer.
How a CU Cancer Center clinical trial saved Ward McNeilly’s life. Plus: Sarcomas explained.
The response rate was nearly 50% for people with breast, colon, pancreatic and other cancers.
These cancers include those that are rare among adults under 40, such as breast, colon, pancreas, kidney, prostate and ovarian cancer.
“I felt any small contribution I might make for sarcoma patients could have a huge impact on them and the way the disease is treated.”
The approval will not only benefit current patients, but will also spur more research into the biology of other rare tumors.
Edited T cells survive and thrive in three patients in the first U.S. trial using this approach.
Epithelioid sarcoma is a rare sub-type of soft tissue sarcoma that often occurs in young adults.
A study shows how “epigenetic” changes can lead to the development of certain cancers, and how to short-circuit the cancer-causing machine...
Some of the most common and deadly cancers receive little attention and resources.
Shared database helps find treatment for cancers too rare to have their own clinical trials.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.